Efficacy of immunotherapy in KRAS-mutant non-small-cell lung cancer with comutations
KRAS-mutant non-small-cell lung cancer is the most common molecular driver of lung
adenocarcinoma in western populations. No KRAS specific therapy has been approved by …
adenocarcinoma in western populations. No KRAS specific therapy has been approved by …
The impact of smoking status on the Progression‐Free survival of Non‐Small cell lung cancer patients receiving Molecularly target therapy or Immunotherapy versus …
X Li, C Huang, X Xie, Z Wu, X Tian… - Journal of Clinical …, 2021 - Wiley Online Library
What is known and Objective Smoking has a notable influence on the efficacy of
medications for lung cancer. Previous studies illustrated the correlation between smoking …
medications for lung cancer. Previous studies illustrated the correlation between smoking …
Survival analysis for non-squamous NSCLC patients harbored STK11 or KEAP1 mutation receiving atezolizumab
X Shang, Z Li, J Sun, C Zhao, J Lin, H Wang - Lung Cancer, 2021 - Elsevier
Objective To analyze the prognostic effect for patients with non-squamous non-small cell
lung cancer (NSCLC) harbored STK11 or KEAP1 (STK11/KEAP1) mutations receiving …
lung cancer (NSCLC) harbored STK11 or KEAP1 (STK11/KEAP1) mutations receiving …
The balance between differentiation and terminal differentiation maintains oral epithelial homeostasis
Y Bai, J Boath, GR White, UGIU Kariyawasam… - Cancers, 2021 - mdpi.com
Simple Summary Oral cancer affecting the oral cavity represents the most common cancer of
the head and neck region. Oral cancer develops in a multistep process in which normal cells …
the head and neck region. Oral cancer develops in a multistep process in which normal cells …
HER2 amplification in advanced NSCLC patients after progression on EGFR-TKI and clinical response to EGFR-TKI plus pyrotinib combination therapy
J Gan, Y Huang, J Liao, L Pang… - OncoTargets and therapy, 2021 - Taylor & Francis
Background HER2 (or ERBB2) amplification is an important mechanism for acquired
resistance to EGFR tyrosine kinase inhibitors (TKI). The benefits of HER2-targeted therapy …
resistance to EGFR tyrosine kinase inhibitors (TKI). The benefits of HER2-targeted therapy …
The mechanisms of resistance to second-and third-generation ALK inhibitors and strategies to overcome such resistance
N Haratake, G Toyokawa, T Seto… - Expert review of …, 2021 - Taylor & Francis
Introduction Anaplastic lymphoma kinase (ALK) inhibitors are widely known to contribute to
the long-term survival of ALK-rearranged non-small cell lung cancer (NSCLC) patients …
the long-term survival of ALK-rearranged non-small cell lung cancer (NSCLC) patients …
Current knowledge about mechanisms of drug resistance against ALK inhibitors in non-small cell lung cancer
Simple Summary Lung cancer is a devastating disease, with non-small cell lung cancer
(NSCLC) being the most common subtype. With the development of novel targeted …
(NSCLC) being the most common subtype. With the development of novel targeted …
Pharmacological inhibitors of anaplastic lymphoma kinase (ALK) induce immunogenic cell death through on-target effects
Immunogenic cell death (ICD) is clinically relevant because cytotoxicants that kill malignant
cells via ICD elicit anticancer immune responses that prolong the effects of chemotherapies …
cells via ICD elicit anticancer immune responses that prolong the effects of chemotherapies …
Development and validation of an HPLC–MS/MS method to simultaneously quantify alectinib, crizotinib, erlotinib, gefitinib and osimertinib in human plasma samples …
A van Veelen, R van Geel, R Schoufs… - Biomedical …, 2021 - Wiley Online Library
A liquid chromatography–tandem mass spectrometry method was developed and validated
to quantify alectinib, crizotinib, erlotinib and gefitinib. This assay can be combined with our …
to quantify alectinib, crizotinib, erlotinib and gefitinib. This assay can be combined with our …
Patient-reported and end-of-life outcomes among adults with lung cancer receiving targeted therapy in a clinical trial of early integrated palliative care: A secondary …
LA Petrillo, A El-Jawahri, ER Gallagher… - Journal of pain and …, 2021 - Elsevier
Context Targeted therapy has revolutionized lung cancer treatment and markedly increased
survival, though data are lacking on patient-reported and end-of-life (EOL) outcomes among …
survival, though data are lacking on patient-reported and end-of-life (EOL) outcomes among …